Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress by Zaugg, K et al.
Zurich Open Repository and Archive
University of Zurich
Main Library
Winterthurerstr. 190
CH-8057 Zurich
www.zora.uzh.ch
Year: 2011
Carnitine palmitoyltransferase 1C promotes cell survival
and tumor growth under conditions of metabolic stress
Zaugg, K; Yao, Y; Reilly, P T; Kannan, K; Kiarash, R; Mason, J; Huang, P;
Sawyer, S K; Fuerth, B; Faubert, B; Kalliomäki, T; Elia, A J; Luo, X; Nadeem, V;
Bungard, D; Yalavarthi, S; Growney, J D; Wakeham, A; Moolani, Y; Silvester, J;
Ten, A Y; Bakker, W; Tsuchihara, K; Berger, S L; Hill, R P; Jones, R G; Tsao, M;
Robinson, M O; Thompson, C B; Pan, G; Mak, T W
http://www.ncbi.nlm.nih.gov/pubmed/21576264.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Zaugg, K; Yao, Y; Reilly, P T; Kannan, K; Kiarash, R; Mason, J; Huang, P; Sawyer, S K; Fuerth, B; Faubert,
B; Kalliomäki, T; Elia, A J; Luo, X; Nadeem, V; Bungard, D; Yalavarthi, S; Growney, J D; Wakeham, A;
Moolani, Y; Silvester, J; Ten, A Y; Bakker, W; Tsuchihara, K; Berger, S L; Hill, R P; Jones, R G; Tsao, M;
Robinson, M O; Thompson, C B; Pan, G; Mak, T W (2011). Carnitine palmitoyltransferase 1C promotes
cell survival and tumor growth under conditions of metabolic stress. Genes &amp; Development,
25(10):1041-1051.
http://www.ncbi.nlm.nih.gov/pubmed/21576264.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Zaugg, K; Yao, Y; Reilly, P T; Kannan, K; Kiarash, R; Mason, J; Huang, P; Sawyer, S K; Fuerth, B; Faubert,
B; Kalliomäki, T; Elia, A J; Luo, X; Nadeem, V; Bungard, D; Yalavarthi, S; Growney, J D; Wakeham, A;
Moolani, Y; Silvester, J; Ten, A Y; Bakker, W; Tsuchihara, K; Berger, S L; Hill, R P; Jones, R G; Tsao, M;
Robinson, M O; Thompson, C B; Pan, G; Mak, T W (2011). Carnitine palmitoyltransferase 1C promotes
cell survival and tumor growth under conditions of metabolic stress. Genes &amp; Development,
25(10):1041-1051.
Carnitine palmitoyltransferase 1C promotes cell survival
and tumor growth under conditions of metabolic stress
Abstract
Tumor cells gain a survival/growth advantage by adapting their metabolism to respond to
environmental stress, a process known as metabolic transformation. The best-known aspect of
metabolic transformation is the Warburg effect, whereby cancer cells up-regulate glycolysis
under aerobic conditions. However, other mechanisms mediating metabolic transformation
remain undefined. Here we report that carnitine palmitoyltransferase 1C (CPT1C), a
brain-specific metabolic enzyme, may participate in metabolic transformation. CPT1C
expression correlates inversely with mammalian target of rapamycin (mTOR) pathway
activation, contributes to rapamycin resistance in murine primary tumors, and is frequently
up-regulated in human lung tumors. Tumor cells constitutively expressing CPT1C show
increased fatty acid (FA) oxidation, ATP production, and resistance to glucose deprivation or
hypoxia. Conversely, cancer cells lacking CPT1C produce less ATP and are more sensitive to
metabolic stress. CPT1C depletion via siRNA suppresses xenograft tumor growth and
metformin responsiveness in vivo. CPT1C can be induced by hypoxia or glucose deprivation
and is regulated by AMPKα. Cpt1c-deficient murine embryonic stem (ES) cells show
sensitivity to hypoxia and glucose deprivation and altered FA homeostasis. Our results
indicate that cells can use a novel mechanism involving CPT1C and FA metabolism to protect
against metabolic stress. CPT1C may thus be a new therapeutic target for the treatment of
hypoxic tumors.
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Tumor cells gain a survival/growth advantage by adapting their metabolism to respond to environmental stress,
a process known as metabolic transformation. The best-known aspect of metabolic transformation is the Warburg
effect, whereby cancer cells up-regulate glycolysis under aerobic conditions. However, other mechanisms mediating
metabolic transformation remain undefined. Here we report that carnitine palmitoyltransferase 1C (CPT1C),
a brain-specific metabolic enzyme, may participate in metabolic transformation. CPT1C expression correlates
inversely with mammalian target of rapamycin (mTOR) pathway activation, contributes to rapamycin resistance in
murine primary tumors, and is frequently up-regulated in human lung tumors. Tumor cells constitutively expressing
CPT1C show increased fatty acid (FA) oxidation, ATP production, and resistance to glucose deprivation or hypoxia.
Conversely, cancer cells lacking CPT1C produce less ATP and are more sensitive to metabolic stress. CPT1C
depletion via siRNA suppresses xenograft tumor growth and metformin responsiveness in vivo. CPT1C can be
induced by hypoxia or glucose deprivation and is regulated by AMPKa. Cpt1c-deficient murine embryonic stem (ES)
cells show sensitivity to hypoxia and glucose deprivation and altered FA homeostasis. Our results indicate that cells
can use a novel mechanism involving CPT1C and FA metabolism to protect against metabolic stress. CPT1C may
thus be a new therapeutic target for the treatment of hypoxic tumors.
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Themetabolism of human cancers shows adaptations that
promote survival under conditions of metabolic stress
(Brown and Wilson 2004; Gatenby and Gillies 2004; Pan
and Mak 2007). Tumor cells typically undergo ‘‘metabolic
transformation’’ that is modulated by AMP-activated pro-
tein kinase (AMPK) and mammalian target of rapamycin
(mTOR) (Plas and Thompson 2005; Shaw 2006; Gwinn
et al. 2008). AMPK is activated under poor nutrient
Present addresses: 17Department of Pathobiology, Faculty of Veterinary
Medicine, University of Utrecht, 3508 TD Utrecht, The Netherlands;
18Research Center for Innovative Oncology, National Cancer Center 6-5-1
Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
19These authors contributed equally to this work.
20These authors contributed equally to this work.
21Corresponding author.
E-MAIL tmak@uhnres.utoronto.ca; FAX (416) 204-5300.
Article is online at http://www.genesdev.org/cgi/doi/10.1101/gad.1987211.
Freely available online through the Genes & Development Open Access
option.
GENES & DEVELOPMENT 25:1041–1051  2011 by Cold Spring Harbor Laboratory Press ISSN 0890-9369/11; www.genesdev.org 1041
 Cold Spring Harbor Laboratory Press on September 19, 2011 - Published by genesdev.cshlp.orgDownloaded from 
conditions, whereas mTOR activation is triggered by high
levels of glucose and amino acids. Upon induction of
metabolic transformation, cancer cells limit their energy
consumption and enhance energy production using
a program characterized by increased glycolysis (Brown
and Wilson 2004; Shaw 2006). However, several lines of
evidence implicate fatty acid (FA) oxidation (FAO) as
contributing to metabolic transformation (Yamashita
et al. 2000; Liu 2006; Swinnen et al. 2006; Hirsch et al.
2010). Expression of genes involved in lipid metabolism
is increased in tumors (Hirsch et al. 2010), and mono-
acylglycerol lipase (Maglione et al. 2001), an enzyme
that liberates free FA from lipid stores, promotes cancer
pathogenesis (Nomura et al. 2010). Interestingly, the
cancer-promoting effect of MAGL does not seem to
involve FAO mediated by the usual carnitine palmitoyl-
transferase 1 (CPT1) isozymes (Nomura et al. 2010). FAO
is also increased in response to glucose deprivation by
the p53-dependent induction of guanidinoacetate meth-
yltransferase (GAMT), but the mechanism is unknown
(Ide et al. 2009).
FAO is controlled at the step of FA import into the
mitochondria, a process executed by tissue-specific iso-
forms of CPT1 (Kerner and Hoppel 2000). CPT1A func-
tions in the liver and most other tissues, CPT1B functions
predominantly in muscle, and CPT1C functions in the
brain (Kerner and Hoppel 2000; Price et al. 2002; Ramsay
and Zammit 2004). Like CPT1A and CPT1B, the brain-
specific CPT1C isoform displays high-affinity binding to
malonyl-CoA, but enzymatic activity has not been ob-
served using conventional substrates (Price et al. 2002;
Ramsay and Zammit 2004; Wolfgang et al. 2006; Sierra
et al. 2008). Gene-targeting studies have demonstrated
that Cpt1c is not essential in mice but that the animals
exhibit reduced FAO (Wolfgang et al. 2006, 2008).
The precise roles of FAO and CPT1 enzymes in cancer
cells experiencing metabolic stress remain unknown.
In response to glucose deprivation, AMPK induces ac-
tivation of a p53-dependent metabolic checkpoint that
promotes cell survival (Jones et al. 2005). Similarly,
treatment of human cancer and normal cells with the
AMPK activators metformin or aminoimidazole carbox-
amide ribonucleotide (AICAR) increases FAO. Further-
more, both metformin and AICAR selectively inhibit
the growth of p53-deficient tumors in vivo (Buzzai et al.
2007). These findings suggest that FAO induction down-
stream from AMPK activation may be a survival/growth
strategy employed by cancer cells subjected tometabolic
stress. However, many of the gene(s) and pathway(s) in-
volved have yet to be elucidated.
In this study, we identify CPT1C as a gene that is fre-
quently expressed in tumors and up-regulated in response
to metabolic stress. Strikingly, CPT1C expression in tumor
cells correlates inversely with both mTOR pathway acti-
vation and sensitivity to the mTOR inhibitor rapamycin.
Enhanced CPT1C expression increases FAO and ATP pro-
duction and protects cells from death induced by glucose
deprivation or hypoxia. Furthermore, CPT1C expression is
induced by metabolic stress in an AMPKa-dependent
manner. Conversely, cells deficient in CPT1C show re-
duced ATP production, altered FA homeostasis, and height-
ened sensitivity to hypoxia or glucose deprivation. Our
findings suggest a new approach for cancer therapies based
on manipulating FA metabolism.
Results
Identification of CPT1C as a potential contributor
to tumor cell metabolic transformation
Our isolation of CPT1C as a gene potentially involved in
tumor cellmetabolic transformation occurred as the result
of the unexpected confluence of two independent screen-
ing methods designed to detect transcripts of interest in
cancer biology. The first method, intended to identify novel
p53-activated transcripts, employed a cDNA microarray
screen based on the differential activation of a temperature-
sensitive form of p53 in transformed mouse erythroleuke-
mia cells (DP16.1/p53ts) that lack endogenous p53. The
second method, intended to identify genes conferring
rapamycin resistance inmousemammary tumor lines, was
based on genetically engineered murine primary tumors
driven by mammary-targeted overexpression of a human
ERBB2 cDNA in the context of Ink4a deletion. In this
second screen, rapamycin sensitivity correlated positively
with high expression of a set of coregulated genes (Pik3ca,
Frap1, Pik3r1, Erbb3, and Pik3r3) that drive the mTOR
pathway; the sum of the mRNA expression levels of these
genes was termed the mTOR index (Supplemental Fig.
S1A, top).
The results of the first screening method revealed that
a partial cDNA encoding Cpt1c was up-regulated fourfold
upon p53 activation (Supplemental Fig. S1B), and that
Cpt1c was the only Cpt gene to show putative responsive-
ness to p53 (Supplemental Fig. S1C). Serendipitously, the
results of the second screening method also identified
Cpt1c as a gene of interest (Supplemental Fig. S1A, bottom).
Most significantly, in the 168 tumors of the 214 analyzed
for which the mTOR index fell below the mean, 108 of
them exhibited Cpt1c expression greater than the overall
mean for this gene (Fig. 1A). The emergence of Cpt1c in
both screens pinpointed this molecule as being of potential
importance to the bioenergetics of cancer cells.
Validation of Cpt1c as a rapamycin resistance factor
To validate the correlation between lowCpt1c expression
and rapamycin sensitivity, we examined the rapamycin
sensitivity of several of our 214 primary tumors in mouse
xenograft models. Cells from tumors representative of
either lowmTOR index/highCpt1c expression (Cpt1c high)
or high mTOR index/low Cpt1c expression (Cpt1c low)
were implanted into nude mice. These mice were treated
with rapamycin for 14 d and new tumor formation was
monitored. Malignancies derived from Cpt1c-high tumors
were more resistant to rapamycin (tumor growth inhibition
[TGI] index of ;40% vs. vehicle-treated controls) than
those derived from Cp1c-low tumors (TGI of >80%) (Fig.
1B). Thus, in general, the Cpt1cmRNA level in a given
tumor correlates inversely with its mTOR index and
rapamycin sensitivity.
Zaugg et al.
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CPT1C is up-regulated in human lung cancers
Since Cpt1c mRNA expression appeared to give tumors
a growth advantage in mice, we next asked whether
human CPT1C might be up-regulated in patient cancer
samples. We used real-time RT–PCR to determine CPT1C
mRNA levels in paired normal and tumor tissues from 19
patients with non-small-cell lung carcinoma (NSCLC).
Where both the normal and tumor tissues of a patient
showed detectable levels of CPT1C, CPT1C mRNA was
up-regulated in tumor tissue compared with matched
normal lung tissue in 81% (13 out of 16) of cases (Fig. 2,
top). Because our early studies suggested that CPT1C
might be a p53-related transcript, we examined whether
CPT1C up-regulation might be a bystander effect of p53
activation. We examined the status of p53 in our NSCLCs
by immunohistochemistry (IHC) and cDNA sequenc-
ing and found no correlation between p53 expression or
mutation and CPT1C mRNA expression (Fig. 2, bottom).
Thus, CPT1C up-regulation in human NSCLCs is not
a bystander effect of p53 activation. These data imply that
CPT1C provides a p53-independent growth advantage to
a tumor, and that CPT1C expressionmust be controlled by
additional factors that are as yet unknown.
CPT1C up-regulation induces resistance
to nutrient deficiency
In order to directly examine the functional consequences
of CPT1C expression, we generated a line of MCF-7
cancer cells stably overexpressing Flag-tagged CPT1C
(Fig. 3A). We assessed whether CPT1C overexpression
had a direct effect on mTOR signaling by examining the
phosphorylation of S6K and 4E-BP1, two key effectors of
Figure 1. Cpt1c expression correlates inversely
with mTOR activation and protects cancer cells
against rapamycin. (A) Correlation of Cpt1c ex-
pression with mTOR index. Gene expression
microarray profiling was performed for 214 mu-
rine primary tumors engineered to express hu-
man ERBB2 cDNA. The mTOR index is the
average of the mean centered expression (MCE)
values of the mTOR pathway genes Pik3ca,
Frap1, Pik3r3, Pik3r1, and Erbb3. Cpt1c results
are the mean MCE value obtained for each tumor
using two separate probes. All expression data
were determined using Agilent two-color micro-
array and are reported as the log2 ratio of the
signal intensity of cy3-labeled versus cy5-labeled
hybridizations. (B) Correlation of Cpt1c expres-
sion with rapamycin sensitivity in vivo. Cells
from selected tumors in A with a high mTOR
index and low Cpt1c or cells from tumors in A
with a low mTOR index and high Cpt1c were
injected into nude mice and the animals were
treated with vehicle (control) or rapamycin for 14
d. New growths were measured at the indicated
times; two examples for each group are shown.
(TGI) Tumor growth inhibition index.
Figure 2. CPT1c is overexpressed in human lung tumors. (Top)
Levels of CPT1C mRNA were assayed in human NSCLC
tumors and matched normal lung tissues using real-time RT–
PCR. Results are the fold change in CPT1C mRNA levels in
tumor tissue compared with the matched normal tissue from
the same patient. (Bottom) p53 status and mutations are shown
for the tumors in the top panel. (IHC) Immunohistochemical
staining to detect p53; (cDNA) sequence of p53 exons 4–7; (wt)
only wild-type p53 detected; (fs) frameshift mutation.
CPT1C protects against metabolic stress
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the mTOR pathway. However, no differences were de-
tected between CPT1C-overexpressing and control cells
(Supplemental Fig. S2). Thus, CPT1C does not directly
modulate mTOR signaling.
Because CPT1 proteins are involved in the catabolism of
FA to produce ATP, we tested whether our CPT1C-over-
expressing MCF-7 cells demonstrated increased FAO and
ATP production. When FAO was measured using 14C-
palmitic acid as a substrate (see theMaterials andMethods),
we found that FAO was significantly increased in CPT1C-
overexpressing cells compared with vector-transfected con-
trols (Fig. 3B). CPT1C-overexpressing cells also produced
significantly more ATP than control cells (Fig. 3C). In
addition, CPT1C-overexpressing cells grew significantly
better than controls under hypoxia (Fig. 3D) and in limited
glucose (Fig. 3E). Taken together, our data suggest a model
in which a high level of CPT1C expression facilitates
energy production from FA and provides advantages that
enhance cell growth under conditions of poor nutrient
supply.
CPT1C depletion confers sensitivity to rapamycin
and metabolic stress
We next asked whether CPT1C loss of function might
confer sensitivity to factors that exert metabolic stress.
We designed siRNAs to deplete CPT1C in cancer cells,
and used quantitative RT–PCR to confirm an;70%–80%
reduction in CPT1C mRNA in siRNA-treated MCF-7
cells compared with controls (Supplemental Fig. S3A). In
order to determine whether CPT1C depletion might alter
rapamycin sensitivity, we treated the HCT116 human
colon cancer cell line with our CPT1C siRNAs. HCT116
cells are partially resistant to rapamycin, with a GI50 > 10
nM (Buck et al. 2006). However, upon CPT1C depletion,
these cells showed a significant increase in rapamycin
sensitivity as compared with HCT116 cells treated with
control siRNA (Fig. 4A).
To test whether loss of CPT1C also hindered growth in
a hypoxic environment, MCF-7 cells transfected with con-
trol or CPT1C-specific siRNA were grown for up to 3 d in
0.2% oxygen. Fewer cells were detected in cultures of
CPT1C siRNA-expressing cells than in cultures of control
siRNA-expressing cells after 1 d in hypoxia, and the magni-
tude of this difference increased as the time in hypoxia was
extended (Fig. 4B). Similar results were obtained when
CPT1C was depleted in Hs578T cells (Supplemental Fig.
S3B). CPT1C depletion did not affect the growth of either
MCF-7 or Hs578T cells under normoxia (Supplemental
Fig. S3C,D). Notably, under conditions of glucose depri-
vation, ATP production wasmarkedly impaired inMCF-7
cells transfected with CPT1C siRNA (Fig. 4C).
Our earlier results implied that CPT1C likely stimu-
lates ATP production by effects on FAO. We therefore
investigated whether CPT1C depletion sensitized cells to
a glycolysis inhibitor. We cultured MCF-7 cells transfected
with one of two different CPT1C siRNAs (or control siRNA)
for 5 d in the presence of increasing doses of 2-deoxyglucose
(2-DG). At intermediate doses of 2-DG, theCPT1C-depleted
cells showed significantly reduced growth compared with
controls (Fig. 4D). Similar results were obtained with
CPT1C-depleted A549 human lung cancer cells (Supple-
mental Fig. S3E). These data support our hypothesis that
CPT1C expression can facilitate ATP production from
Figure 3. CPT1C overexpression alters FAO, ATP
production, and responses to metabolic stress. (A)
Validation. MCF-7 cells were stably transfected with
control vector or vector expressing Flag-tagged
CPT1C protein. Flag-CPT1C expression was con-
firmed by immunoblotting. (B) Increased FAO. FAO
was determined in MCF-7 cells overexpressing
CPT1C or control vector as described in the Mate-
rials and Methods. Results are mean counts per
minute (cpm) 6 SD of triplicates. (*) P < 0.05; (**)
P < 0.01; (***) P < 0.005 for all figures. (C) Increased
ATP production. MCF-7 cells overexpressing CPT1C
or control vector were evaluated for ATP production
as described in the Materials and Methods. Results
are the mean ATP production 6 SD of triplicates.
(D) Increased resistance to hypoxia. MCF-7 cells
overexpressing CPT1C or control vector were cul-
tured for the indicated number of days in 0.2% O2,
and cell growth was measured by sulforhodamine B
(SRB) staining (see the Materials and Methods). Re-
sults shown are the mean growth 6 SD of triplicates
relative to untreated controls. (E) Increased resis-
tance to glucose deprivation. MCF-7 cells overex-
pressing CPT1C or control vector were cultured in
the indicated concentrations of glucose for 5 d. Cell
growth was measured by SRB staining as for D.
Zaugg et al.
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FAO and enhance the growth of cancer cells subjected to
various forms of metabolic stress.
CPT1C depletion reduces tumor growth
in xenograft models
Because many solid tumors show the ability to overcome
metabolic stress, we examined the impact of CPT1Cdeple-
tion on tumor growth in mouse xenograft models. We gen-
erated CPT1C shRNA-expressing retroviruses based on
our CPT1C siRNA1 sequence and transduced them—or
retroviruses expressing control GFP-shRNA—into the
MDA-MB-468 human breast cancer cell line. These cells
were then implanted into nude mice and tumor growth
was monitored for ;10 wk. Tumors arising from cells
expressing CPT1C shRNA grew much more slowly than
did control tumors (Fig. 5A), indicating that CPT1C
contributes significantly to solid tumor growth.
We next examined whether depletion of CPT1C in a
xenograft model could alter the effects of the AMPK
agonist metformin on tumors. Metformin is thought to
exert its anti-cancer effects by reducing free glucosewithin
the tumor microenvironment; however, this agent con-
currently enhances cellular responses to metabolic stress.
We introduced CPT1C or control shRNA into HCT116
cells, implanted them in nude mice, and treated the
animals with PBS or metformin for 21 d. We found that
the CPT1C-depleted tumors grewmuch more slowly than
controls and were not responsive to metformin treatment
(Fig. 5B). In order to confirm that this metformin was
indeed active within xenograftedmice, we isolated tumors
from metformin-treated mice implanted with untrans-
duced HCT116 cells and immunoblotted protein lysates
to examine the status of AMPK. An increase in active
phospho-AMPK was detected, as well as enhanced phos-
phorylation of the AMPK substrate ACC (Supplemental
Fig. S4). Thus, metformin successfully activated AMPK in
cancer cells, as expected.
Taken together, these data indicate that depletion of
CPT1C reduces the growth of tumors in vivo, and
imply that CPT1C may function in a pathway down-
stream from metformin in cancer cell metabolic trans-
formation.
CPT1C is up-regulated in response to hypoxia in vivo
Our data indicated that CPT1C expression provided a
growth advantage to tumor cells under conditions ofmeta-
bolic stress. We therefore hypothesized that such stress
might alter the regulation of the CPT1C gene. To test this
theory, we first cultured HCT116 cells in 0.2% oxygen for
72 h and monitored levels of CPT1C protein. Immuno-
blotting was performed using an antiserum raised against
a CPT1C peptide and validated in mutant mouse tissues
(see Fig. 7B, below). We found that CPT1C protein was
clearly induced after 24 h in hypoxia and sustained over
72 h (Fig. 6A). CPT1C protein induction was not apparent
for cells in normoxia at any time point. We then inves-
tigated whether hypoxia applied in vivo could also up-
regulate CPT1C. We subjected tumor-bearing PyMT
transgenic mice (Guy et al. 1992) to chronic hypoxia or
normoxia (see the Materials and Methods) and analyzed
tumors and normal tissues from these animals for EF5
(hypoxia marker) and Cpt1c mRNA. As expected, tumors
from hypoxic PyMT mice showed an ;300% increase in
EF5 staining compared with normoxic controls (Supple-
mental Fig. S5A). Strikingly, in situ hybridization revealed
that Cpt1c expression was increased only in EF5+ hypoxic
Figure 4. CPT1C depletion confers sensitivity to
rapamycin and metabolic stress. (A) Rapamycin
sensitivity. HCT116 cells were transfected with
siRNA against CPT1C or control siRNA (sicontrol).
Transfected cells were treated with the indicated
concentrations of rapamycin for 5 d and cell growth
was measured using SRB staining as for Figure 3D.
(B) Sensitivity to hypoxia. MCF-7 cells were trans-
fected with no siRNA (lipo), luciferase siRNA (con-
trol), or CPT1C siRNA1 or siRNA2. Transfected
cells were exposed to hypoxia for the indicated
number of days and cell growth was measured by
SRB staining as for Figure 3D. (C) Reduced ATP
production. PC3 cells were transfected with CPT1C
or sicontrol siRNA and cultured in glucose-free
medium for the indicated times. ATP production
was evaluated as for Figure 3C. (D) Sensitivity to
glycolytic inhibition. MCF-7 cells were transfected
with control siRNA or CPT1C siRNA1 or siRNA2
and the indicated concentrations of 2-DG were
added at 24 h post-transfection. After 5 d culture,
cell growth was measured by SRB staining as for
Figure 3D.
CPT1C protects against metabolic stress
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tumors (Fig. 6B). RT–PCR analysis confirmed that three
out of four tumors from hypoxic PyMT mice showed
higher Cpt1c mRNA expression than did tumors from
normoxic controls (Supplemental Fig. S5B). Cpt1c expres-
sion was not induced in any normal tissue under hypoxia
(Supplemental Fig. S5C,D). Thus,Cpt1cmRNA is induced
by hypoxia in vivo in tumor tissues but not in normal
tissues, suggesting that low oxygen tension combinedwith
Figure 5. Sustained depletion of CPT1C
reduces tumor growth in xenografts. (A)
CPT1C depletion inhibits human breast
cancer cell growth in vivo. MDA-MB-468
cells were infected with retroviruses
expressing pRS-Cpt1c shRNA or pRS-GFP
shRNA (control) and injected s.c. into nude
mice (n = 5 per group). Tumors were mea-
sured twice per week for ;10 wk. (Left)
Results are the mean tumor volume 6 SD
of all tumors in a group on the indicated day.
(Right) Representative images of tumors
after excision on day 70 post-implantation.
(B) CPT1C-depleted tumors are not respon-
sive to metformin treatment in vivo.
HCT116 cells were infected with retrovi-
ruses expressing pRS-GFP shRNA or pRS-
CPT1C shRNA, and the infected cells were
injected s.c. into nude mice (n = 5 per
group). The animals were treated once daily
with PBS or metformin (250 mg/kg) for 20 d.
Results are the mean relative tumor growth
of all tumors in a group on the indicated day
after treatment.
Figure 6. CPT1C is induced by metabolic stress
and regulated by AMPK. (A) Induction of CPT1C
protein in a cancer cell line subjected to hypoxia. At
24 h post-seeding, HCT116 cells were cultured in
20% or 0.2% O2 for 24 h, 48 h, or 72 h, and CPT1C
protein was detected by immunoblotting. (GAPDH)
Loading control. (B) Up-regulation of Cpt1c expres-
sion in a hypoxia model in vivo. Tumor-bearing
PyMT mice were injected with the hypoxia marker
EF5 and subjected to hypoxia or normoxia (see the
Materials and Methods). Tumors from the normoxic
(panels a,b) and hypoxic (panels c,d) animals were
examined by bright-field (panels a,c) and dark-field
(panels b,d) microscopy. Cpt1c expression was
detected by in situ hybridization. Bar, 100 mm. (C)
Metformin treatment induces CPT1C expression.
MCF-7 cells were cultured for 48 h in medium with
or without 10 mMmetformin and/or 5 mM glucose,
as indicated. Results are mean relative mRNA
levels 6 SD normalized to Hprt1 expression. (D)
Involvement of AMPK in Cpt1c induction upon
glucose withdrawal or hypoxia. SV40-transformed
wild-type or AMPK-deficient (Prka1/a2 double
knockout; DKO) MEFs were cultured for 24 h in
DMEM with (+) or without () 25 mM glucose and
in 20% or 0.2% O2, as indicated. Cpt1c mRNA
levels were assayed by quantitative PCR. Results are
mean relative mRNA levels 6 SD normalized to
Hprt1 expression.
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the unique circumstances of the tumor microenvironment
can trigger CPT1C up-regulation.
CPT1C mRNA can be regulated by AMPK
To investigate how CPT1C might be regulated in cells
exposed to hypoxia or other metabolic stress, we examined
Cpt1c mRNA induction in cultured mouse embryonic
fibroblasts (MEFs). Since AMPK is a central regulator of
metabolic stress, we first determined whether metformin
treatment could induce CPT1C mRNA expression in
MCF-7 cells. Indeed, metformin increased CPT1CmRNA
levels in these cells in both the presence and absence of 5
mM glucose (Fig. 6C). We then determined Cpt1c mRNA
levels in MEFs carrying a compound mutation of Prkaa1
and Prkaa2, the genes encoding the a subunits of mouse
AMPK. Whereas wild-type MEFs showed an approxi-
mately threefold to fivefold induction of Cpt1c mRNA
over controls under conditions of glucose deprivation and/
or hypoxia, Cpt1c induction was impaired in hypoxic
AMPK-deficient MEFs (Fig. 6D). A modest level of Cpt1c
induction occurred in AMPK-deficient MEFs deprived of
glucose, implying that Cpt1c transcription is also regu-
lated by an AMPK-independent mechanism. These data
show that the induction of CPT1C expression in response
to metabolic stress is at least partly dependent on AMPK.
Loss of Cpt1c function leads to alterations in apoptosis,
FAO, and ATP production
To understand how CPT1C might protect cells against
metabolic stress, we analyzed a murine embryonic stem
(ES) cell line (clone XL823; BayGenomics) heterozygous
for a single gene trap vector insertion into intron 6 of the
Cpt1c gene (Fig. 7A) that prematurely terminates Cpt1c
transcription.We generated ES cells homozygous for the gt
mutation (Supplemental Fig. S6A) and verified their loss of
Cpt1c mRNA using real-time RT–PCR and primers spe-
cific for sequences within exons 3, 7, or 9 of the Cpt1c
gene. Cpt1cgt/gt ES cells were hypomorphic but retained
<1% of normal expression levels of the full-length Cpt1c
mRNA (Supplemental Fig. S6B). Immunoblotting of brain
tissue of Cpt1cgt/gt mice generated from these ES cells
confirmed the absence of CPT1C protein (Fig. 7B).
Despite the normal health and life span of Cpt1cgt/gt
mice, long-term cultures of Cpt1cgt/gt ES cells showed
decreased total cell numbers (Supplemental Fig. S6C) and
reduced ATP production (Supplemental Fig. S6D) com-
pared with Cpt1c+/gt cells. Enhanced apoptosis, increased
caspase-3 and caspase-9 activation, and impaired mito-
chondrial membrane potential were also observed (Sup-
plemental Table S1). Most striking was a dramatic differ-
ence in lipid composition between Cpt1cgt/gt and Cpt1c+/gt
ES cells, in that Cpt1c deficiency led to increased levels
of linoleic, arachidonic, and docosotetraenoic acids, and
decreased levels of oleic acid (Supplemental Table S2).
Electron microscopy of Cpt1cgt/gt cells revealed the pres-
ence of swollen mitochondria exhibiting abnormal inter-
nalmembrane structure and loss of internal cristae density
(Fig. 7C). The mutant mitochondria also contained small
vesicles not found in the mitochondria of Cpt1c+/gt cells.
Intriguingly, the cytoplasm of Cpt1cgt/gt cells showed an
accumulation of lipid droplets that was not present in
Figure 7. Characterization of Cpt1c-defi-
cient ES cells. (A) Diagram of the gene trap
Cpt1c allele in ES cell clone XL823 (BayGe-
nomics) showing the splice acceptor (SA)
site, b-Geo, and polyadenylation site (PA)
integrated into intron 6. (B) Immunoblotting
of CPT1C in extracts of brain tissues from
Cpt1c+/+ (WT), Cpt1cgt/gt (KO), and Cpt1c+/gt
(Het) mice. (Tubulin) Loading control. (C)
Altered morphology. The morphology of
Cpt1c+/gt and Cpt1cgt/gt ES cells was exam-
ined by electron microscopy. Cpt1cgt/gt cells
show cytoplasmic lipid droplets (top) and
swollen mitochondria lacking internal
structure (bottom). Results are representa-
tive of two trials. (D) Increased death under
hypoxia. Cpt1c+/gt and Cpt1cgt/gt cells were
cultured for 24 h under normoxia or hypoxia
(0.2% O2) and cell death was detected using
Annexin V staining and flow cytometry. (E)
Hypoxia-induced acidosis does not cause
the death of Cpt1cgt/gt cells. Cpt1c+/gt and
Cpt1cgt/gt ES cells were treated as in C with
the addition of 100 mM HEPES. Cell death
was measured as for C. (F) Increased death
upon glucose withdrawal. Cpt1c+/gt and
Cpt1cgt/gt ES cells were cultured for 48 h
in DMEM or DMEM with no glucose. Cell
death was measured as for C. For D–F,
results are representative of two trials.
CPT1C protects against metabolic stress
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either Cpt1c+/gt cells (Fig. 7C) or wild-type ES cells (data
not shown). These results are consistent with our siRNA
experiments and demonstrate that Cpt1c deficiency im-
pairs FA metabolism, reduces ATP production, and in-
creases apoptosis.
CPT1C protects ES cells from hypoxia-induced
apoptosis
We next examined the responses of Cpt1c+/gt and Cpt1cgt/gt
ES cells to hypoxia and glucose deprivation. When cultured
for 24 h under hypoxia, 79% of Cpt1cgt/gt cells underwent
apoptosis, whereas only 11% of Cpt1c+/gt cells did so (Fig.
7D). Growth under hypoxia enhances the acidosis of
cultured cells, but the addition of HEPES buffer to the
medium did not prevent the excessive death of hypoxic
Cpt1cgt/gt cells (Fig. 7E). Similarly, withdrawal of glucose
resulted in the death of 34%of Cpt1cgt/gt cells and 17.8% of
Cpt1c+/gt cells but only 5% of control wild-type ES cells
(Fig. 7F; data not shown). Thus, loss of CPT1C function
renders ES cells prone to apoptosis under conditions of
metabolic stress.
Discussion
Solid tumors frequently contain regions of poor oxygen-
ation and experience metabolic stress (Brown and Wilson
2004; Gatenby and Gillies 2004; Pan and Mak 2007).
Cancer cells in these regions are driven to adapt to
survive and grow under these conditions, and this meta-
bolic transformation usually takes the form of increased
glycolysis (Pelicano et al. 2006; Shaw 2006). However,
other cellular components can serve as energy sources for
cancers when nutrient depletion or other metabolic stress
triggers the activation of alternative pathway(s) to main-
tain bioenergetic supply (Pan and Mak 2007). We sought
to target genes in these alternative metabolic pathways,
and demonstrate here that CPT1C is a novel gene that
protects cells from metabolic stress.
Our work shows that CPT1C is a potential alternative
energy supply gene that is induced in tumors during the
process of metabolic transformation. Constitutive expres-
sion of CPT1C increases FAOandATP generation, whereas
depletion of CPT1C decreases ATP production. Knock-
down of CPT1C in human cancer cell lines reduces growth
in vitro under conditions of hypoxia or limited glucose, as
well as new tumor formation in vivo. Moreover, Cpt1c
mRNA is induced by hypoxia and glucose deprivation in
murine cells as well as in tumors, and this regulation
depends on a mechanism that involves activated AMPK.
Finally, murine ES cells lacking Cpt1c exhibit mitochon-
drial membrane abnormalities, altered lipid homeosta-
sis, decreased growth, and increased caspase-mediated
cell death. Taken together, our results suggest that CPT1C
may be a regulator of FA homeostasis and involved in the
modulation of bioenergetics that occurs in tumors experi-
encing metabolic stress.
Our results expand our knowledge of the function of this
unusual CPT family member. CPT1C is expressed pre-
dominantly in normal mammalian brains, particularly in
neurons (Price et al. 2002;Wolfgang et al. 2006, 2008; Sierra
et al. 2008). It has been suggested previously that CPT1C
plays an important role in maintaining the energy homeo-
stasis of the whole mouse (Wolfgang et al. 2006, 2008). Our
finding that CPT1C may mediate the adaptation of non-
neuronal tumor cells exposed to metabolic stress suggests
that CPT1C has functions at both the organismal level
(controlling nutrient intake and energy homeostasis) and
the cellular level (protection against acute metabolic
stress). It is not yet clear why this particular CPT1 gene
is induced in malignancies, but we speculate that its gene
product may act on uncharacterized FA substrates that
may be very beneficial for cell survival during metabolic
stress. Consistent with this hypothesis, the FA composi-
tion of cells is altered in cells lacking CPT1C.
Three lines of evidence arising from our study suggest
that one link between CPT1C and tumorigenic adaptation
may be mediated through AMPK. First, mutant MEFs
lacking AMPK showed impaired Cpt1c mRNA induction
in response to hypoxia or glucose deprivation. Second,
metformin, an AMPK agonist, was able to induce Cpt1c
expression. Third, Cpt1c originally came to our attention
in a screen designed to detect p53-related transcripts. Since
AMPK and p53 reportedly activate each other (Jones et al.
2005; Bungard et al. 2010), we propose that a p53–AMPK–
CPT1C axis exists for sensing and responding tometabolic
stress. This p53–AMPK–CPT1C axis might permit the
adaptive utilization of FA as a fuel source to support cell
growth. In tumors where p53 is lost, AMPK may work
with additional factors to induce CPT1C andmaintain cell
survival. Consistent with this hypothesis, we showed that
CPT1C depletion sensitized cancer cells expressing either
wild-type or mutant p53 to glycolytic inhibition, glucose
deprivation, or hypoxia. Conversely, ectopic expression of
CPT1C in cells expressing wild-type p53 conferred re-
sistance to glucose deprivation or hypoxia. However, the
induction of Cpt1cmRNA by glucose withdrawal was not
completely eliminated in cells lacking AMPK, suggesting
that the p53–AMPK–CPT1C axis likely involves addi-
tional, still unidentified players.
Our results are consistent with several reports empha-
sizing the emerging importance of FA metabolism in
tumorigenesis (Menendez and Lupu 2007; Hirsch et al.
2010; Nomura et al. 2010). MAGL up-regulation has been
documented in aggressive cancer cell lines and correlates
with increased free FAs and FA metabolites. Moreover,
pathological MAGL expression can be replaced by the pro-
vision of high fat levels both in vitro and in vivo, indicating
that free FAs are themselves pathogenic (Nomura et al.
2010). We showed that cancer cells under metabolic stress
express CPT1C, and that this CPT1C expression can alter
FA homeostasis. It seems likely that FAs freed by CPT1C-
driven events might be used as a fuel source to drive
metabolic transformation and tumor growth.Under normal
nutrient conditions, we speculate that CPT1C-mediated
FAO induction in a tumor might actually impair its growth
because the availability of the FAs needed to serve as
membrane precursors might be reduced. Thus, as tumors
progress, CPT1C induction may be restricted to areas
where nutrient conditions are poor and the bioenergetics
Zaugg et al.
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of the cell demand fuel from the alternative source repre-
sented by FAs.
Our data indicate that CPT1Cmay be an attractive target
for therapeutic intervention where tumors are hypoxic and
deprived of nutrient sources. We showed in human lung
tumors that CPT1C mRNA is up-regulated independently
of p53, and in mouse tumors that Cpt1c expression
correlates inversely with mTOR pathway activation and
tumor sensitivity to rapamycin. Our xenograft experiments
demonstrated that CPT1C depletion greatly retards the
growth of both breast cancer- and colon cancer-derived
tumors. These results suggest that a CPT1C inhibitor, used
either as a monotherapy or in combination with other anti-
cancer agents, may be a promising new avenue of cancer
treatment.
Materials and methods
Cell lines
Cell lines were maintained in Dulbecco’s modified Eagle’s me-
dium (DMEM) containing 10% fetal bovine serum (FBS). Human
cancer cell lines MCF-7, Hs578T, A549, PC3, MDA-MB-468, and
HCT116 (Bunz et al. 1998) and mouse leukemia cell line DP16.1
were obtained from various sources. MCF-7, A549, PC3, and
HCT116 cells are known to carry wild-type p53; MDA-MB-468
and Hs578T cells express mutant p53 R273H and V157F, re-
spectively. DP16.1 lacks both alleles of p53. AMPKa-deficient
MEFs and matched controls were transformed with SV40 trans-
forming region (Laderoute et al. 2006). XL823, a gene trap ES cell
line targeting Cpt1c (BayGenomics), was maintained as described
previously (Okada et al. 2002).
Murine primary mammary tumors
Primary mammary tumors of 129SV origin Ink4a/ARF/; Tet-O-
Her2V66E; MMTV-rtTA ES cells were induced in adult chimeric
mice by tetracycline administration. Tumors were surgically
resected and minced. Tumor cells were isolated from individual
tumors and passaged in Matrigel (BD BioSciences) prior to in vivo
propagation for two rounds of s.c xenografting into NCR-nude
mice. Tumors were then cryopreserved for later analysis.
For microarray analysis (see legend for Supplemental Fig. S1),
individual primary tumor sections were thawed and dissociated,
and ;1 3 105 cells were injected s.c. into BalbC-nude mice
(approximately five mice per tumor line). When these tumors
reached a volume of ;500–800 mm3, mice were sacrificed and
tumors were surgically removed.
mTOR index
The mTOR index was determined based on the method of Perou
et al. (2000). A simple Pearson correlation algorithm was used to
identify components of the mTOR pathway exhibiting correlated
expression, as described in the legend for Supplemental Figure S1.
Human lung tumor and normal lung tissue samples
Matched tumor and normal lung tissue samples were harvested
from 19NSCLC patients treated at the UHN by surgical resection
without adjuvant chemotherapy. Tumor sampleswere snap-frozen
and stored in liquid nitrogen prior to RNAextraction. p53 IHCwas
performed on tumor tissues that were formalin-fixed and paraffin-
embedded.
RNA isolations
Unless otherwise stated, RNA was extracted from cultured cells
using the standard protocols of the RNeasy Kit (Qiagen). RNAwas
extracted fromNSCLC samples using phenol-chloroform and was
purified using the RNeasy kit (Qiagen). For mouse tumors, tissue
was homogenized in Trizol reagent (Invitrogen) and chloroform-
extracted, and RNA was prepared using the RNeasy kit.
Blotting
Southern and Northern blotting were performed according to
standard protocols (Sambrook et al. 1989). For immunoblotting,
standard protocols (Sambrook et al. 1989) were performed using
affinity-purified rabbit polyclonal antiserum directed against a 15-
amino-acid C-terminal peptide of CPT1C, anti-GADPH antibody
(MAB374, Millipore), anti-tubulin antibody (AA2, Millipore), or
anti-Flag antibody (F1804, Sigma).
Real-time PCR
Unless otherwise stated, RNAwas reverse-transcribed using the
SuperScript II kit (Invitrogen). Real-time PCR was performed
using an SDS 7900 (Becton Dickinson), an ABI 7900HT, or an ABI
PRISM 7900-HT (Applied Biosystems) plus SYBR Green reagent
(Applied Biosystems). Raw values were normalized against exter-
nal control housekeeping genes (Gapdh, Hprt, or b-actin) for the
same cDNA sample. Specific primer sequences are available on
request.
Sulforhodamine B (SRB) cell proliferation assay
Cells were fixed in situ using cold 10% trichloroacetic acid (TCA).
Plates werewashed, 50mL of SRB solution (0.4%w/v) dissolved in
1% (v/v) acetic acid was added to each well, and plates were
incubated for 30 min at room temperature. SRB stains were
solubilized in 10 mMTris-HCl (pH 10.5) and absorbance was read
at 570 nm. Cell numbers were calculated based on standard
curves of known cell dilutions.
siRNA transfection
For CPT1C depletion in human cancer cell lines, cells were seeded
into 96-well plates at 1500–2500 cells per well. At 24 h post-
seeding, cells were transfected with 10 nM siRNA using Lipofect-
amine. CPT1C RNA knockdown efficiency was determined as
follows: Four CPT1C siRNAs (Dharmacon)were transfected either
individually into seeded cells at 40 nM each or as a pool of 10 nM
each. Transfection of 40 nM siRNA targeting luciferase was used
as the negative control (sicontrol). Quantitative RT–PCR was per-
formed as described above at 72 h post-transfection. The sequence
of CPT1C siRNA1 was 59-GAAAUCCGCUGAUGGUGAA-39,
and CPT1C siRNA2 was 59-GACAAAUCCUUCACCCUAA-39.
Metabolic stress stimuli, rapamycin, and metformin
Cells were subjected to metabolic stress and control conditions as
follows. Transfected cells were treated at 24 h post-transfection.
Unless otherwise stated, cells were incubated at 37°C in atmo-
spheric oxygen. For hypoxia, cells were incubated in 0.2% O2 in
a hypoxia incubator (ESBE Scientific) for 1, 2, or 3 d before being
transferred back to normoxia for 4, 3, or 2 d, respectively. For
glucose deprivation, cells were incubated in medium without
glucose, or this medium supplemented with a stock glucose
solution to the concentrations indicated in the figures. 2-DG
(Sigma) andmetformin (Sigma) were prepared as stock solutions
CPT1C protects against metabolic stress
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in PBS and diluted to the required concentrations in standard
medium. Rapamycin (Chemietek) was prepared as a stock solution
in DMSO and diluted to the required concentrations in standard
medium. The appropriate vehicle controls were used for all experi-
ments involving chemical treatments.
FAO
MCF-7 cells (23 106) were incubated for 1 h inKrebs Ringer buffer
with 5 mM glucose. Washed cells were resuspended in buffer
containing 0.5% BSA and 1 mCi [1-14C] palmitic acid (GE Health-
care/Amersham) but no glucose. Cells were seeded in the center
wells of organ culture dishes (Falcon 353037), the lids were sealed
with vacuumgrease, and the disheswere incubated for 4 h at 37°C
in 5% CO2. Upon removal of the dishes from the incubator, 1 mL
of 1MNaOHwas pipetted through a hole in the lid into the outer
ring of each dish, and 300 mL of 2 N HCl was pipetted into each
center well. The holes were resealed with Scotch tape, and the
radioactive CO2 released from the medium in the center well was
collected overnight at room temperature. The following morning,
800 mL ofNaOH from the outer ring of the dishwas added to 5mL
of Ecoscint to determine counts per minute (cpm) attributable to
14CO2 production.
ATP production
Cells were cultured in low glucose (5.6 mM) DMEM containing
10% FBS and seeded into 96-well plates. For CPTC1 loss of
function, cells were transfected at 24 h post-seeding with 40 nM
siRNAs as above. At 48 h post-transfection, the medium was
changed to PBS and ATP levels were measured from time 0 to 24 h
using the CellTiter-Glo Luminescent Cell Viability Assay (Prom-
ega). Cell numbers were measured by direct cell counting for each
time point and used to normalize ATP production levels. Lumines-
cence was measured using a SpectraMax M5 (Molecular Devices).
In situ hybridization
In situ hybridization was performed as described (Hui and Joyner
1993; Skinnider et al. 2001). The full-length mouse Cpt1c ORF
was used as the probe.
In vivo tumor cell exposure to hypoxia
MMTV-PyMT634Mul mice were obtained from the Animal Re-
source Center of the Ontario Cancer Institute. At age 3 mo,
tumor-bearing females were i.p. injected with 0.01 mL/g 10 mM
EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-2,2,3,3,3-pentafluoropropyl
acetamide), which was kindly provided by Dr. Cameron Koch
(University of Pennsylvania). The injected mice were randomly
allocated to the normoxia (n = 4) or chronic hypoxia (n = 5) groups
and sealed into air-tight chambers (Billups-Rothenberg) that were
filled with either outside atmosphere or a humidified mixture of
7% oxygen in nitrogen, respectively. At;3.5 h post-gassing, mice
were sacrificed and tumors of <10 mm in diameter were excised
and snap-frozen in liquid nitrogen for subsequent analysis. Levels
of EF5 within tumors were quantified by IHC using anti-ELK3-51
antibody (provided byDr. C. Koch). The total area of EF5+ staining
in a tumor section (excluding areas of necrosis and connective
tissue) was quantified using the positive pixel algorithm of Aperio
ImageScope (Aperio Technologies).
In vivo shRNA inhibition of tumor growth
The pRS shRNA expression cassettes (Origene) encoding shRNA
directed against CPT1C (sense 59-CGGACTATGTTTCCTCAG
GCGGTGGATTC-39) or GFP (catalog no. TR30001; control) were
packaged into amphotropic retroviruses using transient trans-
fection of Phoenix cells via FuGENE 6 reagent (Roche). Culture
supernatants were collected 2 d after transfection and filtered
(0.45 mm). For retroviral infection, MDA-MB-468 cells or HCT116
cells were cultured for 24 h in 1:1 Phoenix conditioned medium
(DMEM, 10% FBS, 8 mg/mL polybrene; Sigma-Aldrich). Trans-
fection was repeated three times to increase efficiency. Infected
cells were trypsinized, counted, and injected s.c. into nudemice at
53 106 (MDA-MB-468) or 33 106 (HCT116) cells per mouse (five
mice per group). Tumor volumes were measured in situ twice
weekly, and viable tumor volumes were calculated assuming
ellipsoid growth patterns.
Flow cytometry analyses
Cell cycle analysis of ES cells was performed using the BrdU Flow
kit (BD Bioscience). Shifts in mitochondrial membrane potential
were detected using a standard protocol and JC-1 (Stratagene). Cell
fluorescence was detected and analyzed using a flow cytometer
(FACSCalibur, BectonDickinson), CellQuest, and FlowJo software
according to standard protocols. Active caspase-3 was detected by
flow cytometry using the BD Bioscience kit (BD PharMingen).
Cleaved caspase-9 was detected using carboxy-fluorescein-labeled
caspase inhibitors (B-Bridge International, Inc.). Apoptosis was
measured by standard Annexin V (BD Bioscience) and propidium
iodide staining.
Electron microscopy
Cpt1cgt/gt and Cpt1c+/gt ES cells were fixed in 0.1 M phosphate
buffer containing 4% formaldehyde and 0.5% glutaraldehyde,
and treated with 1% osmium tetraoxide. After dehydration in
ethanol gradients and a polymerization step, tissue sections of 70
nm were examined using standard protocols.
Statistics
The paired t-test or unpaired t-test was used for comparisons
where appropriate. For statistical interpretation, P < 0.05 (*) is
considered significant, P < 0.01 (**) is considered highly signif-
icant, and P < 0.005 (***) is considered very highly significant.
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